Bausch Health/$BHC
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About Bausch Health
Bausch Health Companies Inc is a world-wide specialty pharmaceutical, consumer health, and medical device company with a focus on branded products for the gastroenterology, hepatology, neurology and dermatology markets. The company reports revenue in five segments: Salix; International; Solta Medical; Diversified Products and Bausch + Lomb. It generates maximum revenue from the Bausch + Lomb segment.
Ticker
$BHC
Sector
Primary listing
NYSE
Employees
20,700
Headquarters
Laval, Canada
Website
Bausch Health Metrics
BasicAdvanced
$2.8B
28.27
$0.27
0.41
-
Price and volume
Market cap
$2.8B
Beta
0.41
52-week high
$9.49
52-week low
$4.25
Average daily volume
3.4M
Financial strength
Current ratio
1.309
Quick ratio
0.791
Long term debt to equity
14,189.796
Total debt to equity
14,787.755
Interest coverage (TTM)
1.25%
Profitability
EBITDA (TTM)
3,110
Gross margin (TTM)
70.70%
Net profit margin (TTM)
0.99%
Operating margin (TTM)
18.96%
Effective tax rate (TTM)
82.92%
Revenue per employee (TTM)
$480,000
Management effectiveness
Return on assets (TTM)
4.29%
Return on equity (TTM)
-120.00%
Valuation
Price to earnings (TTM)
28.274
Price to revenue (TTM)
0.281
Price to book
-3.63
Price to tangible book (TTM)
-0.16
Price to free cash flow (TTM)
2.51
Free cash flow yield (TTM)
39.84%
Free cash flow per share (TTM)
2.988
Growth
Revenue change (TTM)
7.13%
Earnings per share change (TTM)
-119.52%
3-year revenue growth (CAGR)
6.37%
10-year revenue growth (CAGR)
0.72%
3-year earnings per share growth (CAGR)
28.26%
10-year earnings per share growth (CAGR)
-20.17%
What the Analysts think about Bausch Health
Analyst ratings (Buy, Hold, Sell) for Bausch Health stock.
Bausch Health Financial Performance
Revenues and expenses
Bausch Health Earnings Performance
Company profitability
Bausch Health News
AllArticlesVideos
Bausch Health, Canada Inc. Treatment for Acne Vulgaris, (Pr)CABTREO(TM) (Clindamycin Phosphate, Adapalene and Benzoyl Peroxide Gel), Now Available Through Public Drug Plans of Quebec and Saskatchewan
Accesswire·1 day ago
Bausch + Lomb board members resign after Icahn agreement ends
Reuters·4 days ago
Bausch Health Announces Increase in Shareholding by its Chairperson of the Board and Board Changes
Accesswire·7 days ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
No upcoming events
FAQs
What’s the current market cap for Bausch Health stock?
Bausch Health (BHC) has a market cap of $2.8B as of August 22, 2025.
What is the P/E ratio for Bausch Health stock?
The price to earnings (P/E) ratio for Bausch Health (BHC) stock is 28.27 as of August 22, 2025.
Does Bausch Health stock pay dividends?
No, Bausch Health (BHC) stock does not pay dividends to its shareholders as of August 22, 2025.
When is the next Bausch Health dividend payment date?
Bausch Health (BHC) stock does not pay dividends to its shareholders.
What is the beta indicator for Bausch Health?
Bausch Health (BHC) has a beta rating of 0.41. This means that it is less volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 0.5 would mean it moves half as much as the market.